Posted on January 30th, 2013 by Logan Lafferty
The Norwegian study — supported by the Norwegian Institute of Public Health and the U.S. National Institutes of Health — involved a slightly different H1N1 vaccine from that used in the USA, says Gregory Poland, a professor and vaccine researcher at the Mayo Clinic in Minnesota. Norwegians added an adjuvant to their vaccine, which is intended to produce a stronger immune response.
Tags: adjuvant, Dr. Gregory Poland, H1N1, immune response, Immunology, Infectious Diseases, International, Mayo Clinic Rochester, New Parent Magazine, Norwegian Institute of Public Health, Research, U.S. National Institutes of Health, vaccine
You must be logged-in to the site to post a comment.